CVS:NYE-CVS Health Corporation

EQUITY | Health Care Plans | New York Stock Exchange

Last Closing

USD 56.67

Change

+1.07 (+1.92)%

Market Cap

USD 78.05B

Volume

0.01B

Analyst Target

USD 76.76
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

CVS Health Corp iis an integrated pharmacy health care provider. The Company has three segments: Pharmacy Services, Retail Pharmacy and Corporate.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-03-18 )

Largest Industry Peers for Health Care Plans

ETFs Containing CVS

CFCV 4.71 % 0.00 %

N/A

N/A
RTH VanEck Retail ETF 3.97 % 0.35 %

+1.88 (+0%)

USD 0.19B
SPVU Invesco S&P 500® Enhance.. 3.29 % 0.16 %

+0.73 (+0%)

USD 0.11B
UVAL:SW SPDR® MSCI USA Value UCI.. 2.76 % 0.00 %

+0.43 (+0%)

USD 0.13B
STPL:CA BMO Global Consumer Stapl.. 2.72 % 0.40 %

-0.03 (0%)

CAD 0.04B
UPVLE:SW UBS (Irl) ETF plc - Facto.. 2.29 % 0.00 %

+0.06 (+0%)

USD 0.05B
UPVLD:SW UBS (Irl) ETF plc - Facto.. 2.29 % 0.00 %

+0.19 (+0%)

USD 0.22B
UPVLH:SW 2.29 % 0.00 %

N/A

N/A
RPV Invesco S&P 500® Pure Va.. 2.09 % 0.35 %

+1.75 (+0%)

USD 1.61B
IUVL:SW iShares Edge MSCI USA Val.. 1.98 % 0.00 %

N/A

USD 1.90B
RFDA RiverFront Dynamic US Div.. 1.96 % 0.52 %

+0.63 (+0%)

USD 0.07B
VLUE:AU VanEck MSCI International.. 1.43 % 0.00 %

+0.21 (+0%)

USD 0.24B
VVL:CA Vanguard Global Value Fac.. 0.74 % 0.40 %

+0.58 (+0%)

CAD 0.33B
LUSC:LSE SPDR Barclays 10+ U.S. Co.. 0.43 % 0.00 %

+0.15 (+0%)

USD 0.09B
LCRP:LSE SPDR Barclays 10+ U.S. Co.. 0.42 % 0.00 %

+0.08 (+0%)

USD 0.09B
SUSC:LSE SPDR Barclays 0-3 Year US.. 0.41 % 0.00 %

+0.03 (+0%)

USD 0.22B
SYBN:F SPDR Barclays 10+ U.S. Co.. 0.37 % 0.00 %

+0.15 (+0%)

USD 0.09B
SYBN:XETRA SPDR Barclays 10+ U.S. Co.. 0.37 % 0.00 %

+0.15 (+0%)

USD 0.09B
SYBR:F SSgA SPDR ETFs Europe I P.. 0.30 % 0.00 %

+0.11 (+0%)

USD 0.24B
SYBR:XETRA SPDR Barclays 3-10 U.S. C.. 0.30 % 0.00 %

+0.09 (+0%)

USD 0.24B
IUCB:SW SPDR® Bloomberg 1-10 Yea.. 0.30 % 0.00 %

-0.05 (0%)

USD 0.23B
AGGY WisdomTree Yield Enhanced.. 0.00 % 0.12 %

+0.16 (+0%)

USD 0.94B
BSCP Invesco BulletShares 2025.. 0.00 % 0.10 %

+0.03 (+0%)

USD 3.73B
ESGF 0.00 % 0.40 %

N/A

N/A
ESGL ESGL Holdings Limited Ord.. 0.00 % 0.40 %

+0.05 (+0%)

USD 7.01M
FXG First Trust Consumer Stap.. 0.00 % 0.64 %

+0.67 (+0%)

USD 0.43B
IBDL 0.00 % 0.10 %

N/A

N/A
IHF iShares U.S. Healthcare P.. 0.00 % 0.43 %

+0.43 (+0%)

USD 0.87B
ILTB iShares Core 10+ Year USD.. 0.00 % 0.06 %

+0.42 (+0%)

USD 0.62B
IYK iShares US Consumer Stapl.. 0.00 % 0.42 %

+0.65 (+0%)

USD 1.32B
LQD iShares iBoxx $ Investmen.. 0.00 % 0.15 %

+0.75 (+0%)

USD 34.13B
SPLB SPDR Barclays Long Term C.. 0.00 % 0.08 %

+0.22 (+0%)

USD 0.84B
IG Principal Exchange-Traded.. 0.00 % 0.26 %

+0.09 (+0%)

USD 0.08B
IGLB iShares 10+ Year Investme.. 0.00 % 0.10 %

+0.53 (+0%)

USD 2.09B
IBDT iShares iBonds Dec 2028 T.. 0.00 % 0.10 %

+0.07 (+0%)

USD 1.67B
SSPY Syntax Stratified LargeCa.. 0.00 % 0.00 %

+1.03 (+0%)

USD 0.09B
RWL Invesco S&P 500 Revenue E.. 0.00 % 0.39 %

+1.12 (+0%)

USD 2.53B
SLQD iShares 0-5 Year Investme.. 0.00 % 0.06 %

+0.09 (+0%)

USD 2.17B
VLUE 0.00 % 0.15 %

N/A

N/A
ICAN 0.00 % 0.50 %

N/A

N/A
IUVD:LSE iShares Edge MSCI USA Val.. 0.00 % 0.00 %

+0.04 (+0%)

USD 2.17B
IUVF:LSE iShares Edge MSCI USA Val.. 0.00 % 0.00 %

+4.75 (+0%)

USD 2.17B
IUVL:LSE iShares Edge MSCI USA Val.. 0.00 % 0.00 %

+0.06 (+0%)

USD 2.17B
UC84:LSE UBS Barclays US Liquid Co.. 0.00 % 0.00 %

+4.75 (+0%)

USD 0.07B
UVAL:LSE SPDR® MSCI USA Value UCI.. 0.00 % 0.00 %

+0.31 (+0%)

USD 0.13B
VVAL:LSE 0.00 % 0.00 %

N/A

N/A
USVL:LSE SPDR® MSCI USA Value UCI.. 0.00 % 0.00 %

+0.28 (+0%)

USD 0.13B
QDVI:F iShares IV Public Limited.. 0.00 % 0.00 %

+0.07 (+0%)

USD 2.17B
ZPRU:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

+0.53 (+0%)

USD 0.12B
QDVI:XETRA iShares Edge MSCI USA Val.. 0.00 % 0.00 %

+0.07 (+0%)

USD 2.17B
VGVL:XETRA 0.00 % 0.00 %

N/A

N/A
ZPRU:XETRA SPDR® MSCI USA Value UCI.. 0.00 % 0.00 %

+0.39 (+0%)

USD 0.12B
GBLO 0.00 % 0.00 %

N/A

N/A
NVQ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Care Plans) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -13.51% 13% F 3% F
Dividend Return 0.76% 100% F 39% F
Total Return -12.74% 13% F 4% F
Trailing 12 Months  
Capital Gain -13.68% 13% F 22% F
Dividend Return 3.05% 100% F 52% F
Total Return -10.63% 13% F 24% F
Trailing 5 Years  
Capital Gain -23.10% 13% F 25% F
Dividend Return 11.43% 60% D- 39% F
Total Return -11.66% 13% F 24% F
Average Annual (5 Year Horizon)  
Capital Gain -3.47% 13% F 22% F
Dividend Return -1.47% 13% F 20% F
Total Return 2.00% 100% F 41% F
Risk Return Profile  
Volatility (Standard Deviation) 17.97% 88% B+ 41% F
Risk Adjusted Return -8.19% 13% F 22% F
Market Capitalization 78.05B 75% C 98% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Health Care Plans) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 15.90 100% 96%
Price/Book Ratio 2.00 100% 39%
Price / Cash Flow Ratio 1.79 88% 63%
Price/Free Cash Flow Ratio 8.98 88% 56%
Management Effectiveness  
Return on Equity -1.40% 13% 21%
Return on Invested Capital 9.58% 40% 56%
Return on Assets -0.40% 13% 21%
Debt to Equity Ratio 162.25% 13% 22%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector